ISACs conjugated with TLR7/8/9 agonists have shown the ability to reprogram tumor-associated macrophages and activate dendritic cells, resulting in robust T cell-mediated tumor regression in melanoma and breast cancer models [33,47]. The gene discussed is TLR7; the disease is neoplasm.